- Over the past 10 years, the management of NSCLC has seen the introduction of targeted treatments, from EGFR to ALK and, more recently, PD-L1
- In a recent real-world NSCLC study, less than 30% of patients were treated with a second-line therapy
- NSCLC patients still have a poor prognosis despite these advancements in medicine
to learn more.
SVMPharma is an innovative strategic consultancy and CRO, with a focus in Real World Evidence (RWE) for pharmaceutical and biotechnology companies. SVMPharma delivers clinical trials within UK and Europe.
DISTILL is a new EDC launched by SVMPharma. As a CRO discover the benefits of DISTILL as part of your service offering and take back control of your clinical trials. DISTILL allows you to develop and manage every aspect of your trials from start to finish. Move away from the restrictions and costs associated with legacy systems.
For more information, please visit www.svmpharma.com
and contact us at email@example.com